Bristol Myers Squibb’s Opdivo and Yervoy combination shows unprecedented 10-year survival benefits in advanced melanoma
Bristol Myers Squibb has presented groundbreaking 10-year follow-up data from its CheckMate -067 trial, which highlights the long-term survival benefits of the Opdivo (nivolumab) and ... Read More
Setback for Bristol Myers Squibb: CheckMate -73L trial fails to meet endpoint
Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 CheckMate -73L trial did not achieve its primary endpoint of progression-free survival (PFS) in patients ... Read More
FDA approves Opdivo and Cabometyx combo for advanced kidney cancer treatment
The U.S. Food and Drug Administration (FDA) has officially approved the combination of Bristol Myers Squibb's Opdivo (nivolumab) and Exelixis' Cabometyx (cabozantinib) for the first-line ... Read More
Bristol Myers Squibb’s Opdivo and Yervoy combination approved for metastatic NSCLC in Europe
Bristol Myers Squibb (BMS) has announced a major breakthrough in cancer treatment with the European Commission's (EC) approval of its Opdivo (nivolumab) and Yervoy (ipilimumab) ... Read More
FDA approves Opdivo and Yervoy combination for malignant pleural mesothelioma treatment
Bristol Myers Squibb (BMS) has secured approval from the US Food and Drug Administration (FDA) for a new combination treatment involving Opdivo (nivolumab) and Yervoy ... Read More
FDA approves Opdivo + Yervoy for HCC previously treated with sorafenib
Bristol Myers Squibb has secured approval for the combination of Opdivo (nivolumab) 1 mg/kg and Yervoy (ipilimumab) 3 mg/kg from the US Food and Drug ... Read More
Bristol-Myers Squibb to acquire Celgene in $74bn pharma megadeal
Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately $74 billion. This acquisition will merge two ... Read More